Leap Therapeutics, Inc. (LPTX)

Leap Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	1.5	1.5
Gross Profit	-	-	-	1.5	1.5
Selling, General & Admin	12.85	13.81	11.8	10.77	9.62
Research & Development	57.21	72.13	42.91	30.93	20.19
Operating Expenses	70.06	85.94	54.71	41.7	29.81
Operating Income	-70.06	-85.94	-54.71	-40.2	-28.31
Interest Expense	-	-	-0.05	-0.04	-0.04
Interest & Investment Income	3.13	4.03	0.93	0.01	0.09
Currency Exchange Gain (Loss)	-0.04	-0.01	-0.61	-0.38	0.74
Other Non Operating Income (Expenses)	-	0.51	-	-	-
EBT Excluding Unusual Items	-66.97	-81.41	-54.45	-40.61	-27.52
Other Unusual Items	-0.23	-	-	-	-
Pretax Income	-67.2	-81.41	-54.45	-40.61	-27.52
Income Tax Expense	0.59	-	0.15	-0.02	-0
Net Income	-67.79	-81.41	-54.6	-40.59	-27.51
Preferred Dividends & Other Adjustments	0.23	-	-	-	10.07
Net Income to Common	-68.02	-81.41	-54.6	-40.59	-37.59
Shares Outstanding (Basic)	38	20	11	9	6
Shares Outstanding (Diluted)	38	20	11	9	6
Shares Change (YoY)	83.67%	80.55%	31.94%	44.66%	162.71%
EPS (Basic)	-1.81	-3.98	-4.82	-4.73	-6.34
EPS (Diluted)	-1.81	-3.98	-4.82	-4.73	-6.34
Free Cash Flow	-60.3	-45.15	-49.04	-35.16	-25.96
Free Cash Flow Per Share	-1.61	-2.21	-4.33	-4.10	-4.38
Gross Margin	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-2680.00%	-1887.20%
Profit Margin	-	-	-	-2705.80%	-2505.87%
Free Cash Flow Margin	-	-	-	-2343.80%	-1730.47%
EBITDA	-70.05	-85.93	-54.7	-40.17	-28.27
D&A For EBITDA	0.01	0.02	0.02	0.03	0.03
EBIT	-70.06	-85.94	-54.71	-40.2	-28.31

Updated Mar 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q